Company Description
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV).
The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases.
It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 587 |
| CEO | Marianne De Backer |
Contact Details
Address: 1800 Owens Street, Suite 900 San Francisco, California 94158 United States | |
| Phone | 415 906 4324 |
| Website | vir.bio |
Stock Details
| Ticker Symbol | VIR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001706431 |
| CUSIP Number | 92764N102 |
| ISIN Number | US92764N1028 |
| Employer ID | 81-2730369 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | Chief Executive Officer and Director |
| Dr. Ann M. Hanly Ph.D. | Executive Vice President and Chief Technology Officer |
| Dr. Jeff Calcagno M.D. | Executive Vice President and Chief Business Officer |
| Dr. Klaus Frueh Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Lawrence Corey M.D. | Co-Founder and Scientific Advisor |
| Dr. Louis J. Picker M.D. | Co-Founder and Scientific Advisor |
| Jason O'Byrne | Executive Vice President and Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 10, 2024 | 8-K | Current Report |
| Sep 9, 2024 | 144 | Filing |
| Aug 1, 2024 | 10-Q | Quarterly Report |
| Aug 1, 2024 | 8-K | Current Report |
| Aug 1, 2024 | 8-K | Current Report |
| Jul 10, 2024 | 144 | Filing |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 11, 2024 | 144 | Filing |
| Jun 7, 2024 | 144 | Filing |